

Press release

France



Sanofi becomes a founding member of the Université Paris-Saclay Foundation and provides financial support as part of a sponsorship agreement

Paris, 23 September 2024. Sanofi and Université Paris-Saclay have today signed a sponsorship agreement with the Université Paris-Saclay Foundation. Worth one million euros over a period of four years, the funding will benefit two Université Paris-Saclay Foundation projects in particular. The first project aims to advance knowledge in the field of rare and respiratory diseases, and the second to combat falsified medicines more effectively. This sponsorship, which makes Sanofi a founding member of the Université Paris-Saclay Foundation, is part of Sanofi's links with the Paris-Saclay cluster of Greater Paris, of which the university was also a founding member and led to the [creation of the Paris-Saclay Cancer Cluster \(PSCC\)](#) in February 2022 to accelerate the fight against cancer.

Audrey Duval

Chairwoman, Sanofi France

"We are extremely proud to be associated once again with Université Paris-Saclay, this time through a sponsorship agreement, which is a unique opportunity to synergise the multidisciplinary expertise of our teams around shared topics which are close to our heart, whether it be the search for new treatments or the fight against their adulteration".

An initial project supported by the Université Paris-Saclay Foundation aims to advance knowledge in the field of rare and respiratory diseases. In collaboration with INSPIRE - The Breath Institute - Sanofi's digital and clinical development teams will work to identify new biomarkers through clinical trials, and biological mechanisms and pathways that lead to different disease profiles (progression, response, severity, etc.).

Work will focus in particular on chronic obstructive pulmonary disease (COPD) and on the development and use of general computational methods to analyse the data collected.

A second project aims to combat falsified medicines. This project is coordinated by teams from the Faculty of Medicine and the Faculty of Pharmacy at Université Paris-Saclay, in collaboration with the Global Institute for Standards & Expertise against Fake Medicine (GISEFAM), a transdisciplinary European and transatlantic consortium. The Sanofi and GISEFAM teams will combine their strengths and expertise, with the aim of improving their efficiency in:

- the worldwide traceability of falsification flows and the production chain through the collection of targeted information,
- innovation in industrial product protection,
- management of the entire chain of falsified medicine data worldwide, using high-performance analysis methods
- and the development of innovative authentication methods to identify counterfeits.

Patrick Duvaut

President of the Université Paris-Saclay Foundation

"The Sanofi group embodies the DNA of multidisciplinary excellence perfectly. For Université Paris-Saclay, itself at the cutting edge of the world's best medical and pharmaceutical research, it is an exceptional asset to have them as one of the founding pillars of the Foundation in the development of new paradigms of augmented health for all, via sponsorship and philanthropy".



About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on Euronext: SAN and NASDAQ: SNY

About Université Paris Saclay

Université Paris-Saclay was born from the shared ambition of French universities, *grandes écoles* and national research organisations. As a leading university in Europe and the world, it covers the fields of science and engineering, life sciences and health, and humanities and social sciences. The university's science policy closely intertwines research and innovation, incorporating both basic and applied science to tackle major societal challenges. Université Paris-Saclay offers a varied range of undergraduate to doctorate level degrees, including programmes with its *grandes écoles*, all of which are focused on achieving student success and employability. The university prepares students for an ever-changing world where the ability to think critically, remain agile and renew one's skills are crucial. Université Paris-Saclay also offers a comprehensive range of lifelong learning courses. Located to the south of Paris, the university extends across a vast and rich local area. Its location strengthens both its international visibility and its close ties with its socio-economic partners (major companies, SMEs, start-ups, local authorities, charities).

www.universite-paris-saclay.fr

Press contacts, Sanofi

Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com

Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com

Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com

Press contacts, Université Paris-Saclay

Gaëlle Degrez | + 33 6 21 25 77 45 | gaille.degrez@universite-paris-saclay.fr

Katie O'Dowdall | katie.odowdall@universite-paris-saclay.fr